Scienture to commercially launch REZENOPY through Kindeva collaboration

SCIENTURE (SCNX) HOLDINGS announce that its wholly owned subsidiary, Scienture has entered into a definitive agreement with SUMMIT BIOSCIENCES, a wholly owned subsidiary of Kindeva Drug Delivery, for the exclusive U.S. rights to commercially launch REZENOPY Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024. Under the terms of the collaboration, Kindeva will manufacture and commercially supply REZENOPY Nasal Spray 10mg. Scienture will own the new drug application for REZENOPY in its name and be responsible for the sales, marketing and distribution of the product in the U.S. through Scienture’s commercial operations infrastructure.